Sintilimab plus chemo for resected mucosal melanoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mucosal melanoma that has been completely removed by surgery with clear margins.
- Your tumor must be PD-L1 positive (a lab test shows CPS ≥ 1).
- You start the study drug within 13 weeks after surgery, once the wound has healed.
- You are at least 18 years old and in generally good health (able to care for yourself).
- You have not taken any anti-PD-1 or anti-PD-L1 drugs before.
- You do not have active autoimmune diseases, severe infections, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this treatment can help control the cancer.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.